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Abstract: Endometriosis is a chronic disease primarily affecting women of childbearing age, 
in which endometriotic lesions form outside the uterus, typically leading to painful symptoms, 
fatigue, and infertility. The symptoms of endometriosis may cause significant impairment in quality 
of life and represent a substantial economic burden to patients, families, and society. There is no 
cure for endometriosis; management consists of alleviating pain and other symptoms, reducing 
endometriotic lesions, and improving quality of life. Recurrence after surgical intervention is 
common, while the clinical evidence to support the efficacy and safety of many medications cur-
rently used in endometriosis is limited. Dienogest is an oral progestin that has been investigated 
extensively in the treatment of endometriosis in two clinical programs performed in Europe and 
Japan, including dose-ranging, placebo-controlled, active comparator-controlled, and long-term 
(up to 65 weeks) studies. These studies demonstrated that dienogest 2 mg daily effectively alleviates 
the painful symptoms of endometriosis, reduces endometriotic lesions, and improves indices of 
quality of life. Dienogest showed a favorable safety and tolerability profile in these studies, with 
predictable adverse effects, high rates of patient compliance, and low withdrawal rates. This review 
article describes the clinical trial evidence that characterizes the efficacy and safety of dienogest 
in endometriosis, including two studies characterizing dienogest in long-term use. The relevance 
of these findings to the management of endometriosis in clinical practice is discussed.
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Endometriosis: a chronic, painful disease
Endometriosis is a chronic, estrogen-dependent disease that affects approximately 10% 
of women of reproductive age, with a peak incidence in the age range of 25–30 years.1–3 
Endometriosis is characterized by the formation of endometriotic lesions outside the 
uterus, including the ovaries and other pelvic structures. These lesions cause a chronic, 
inflammatory reaction, which can lead to the formation of scar tissue and adhesions.4 
Women with endometriosis frequently experience symptoms of dysmenorrhea, premen-
strual pain, dyspareunia, and chronic fatigue.5 Endometriosis can also interfere with 
functioning of the bowel or bladder, depending on the site where endometriotic lesions 
develop. Up to 50% of women with endometriosis experience infertility.6 However, 
the clinical presentations of endometriosis can vary widely, and many affected women 
are asymptomatic.7 No clear relationship exists between the extent of endometriotic 
lesions and a woman’s symptoms.
Quality of life studies show that symptoms of endometriosis impact on many aspects 
of a woman’s life, including work and education, relationships, and social functioning.8–14 International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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As symptoms become more severe, quality of life is reduced 
further. In a recent international survey, women with endo-
metriosis reported a substantial 38% reduction in work pro-
ductivity, which was attributable primarily to reduced work 
effectiveness in the presence of pelvic pain.15 Endometriosis 
also impacts mental health, with one study showing that 87% 
of the women investigated with endometriosis had depressive 
symptoms and 88% had anxiety.16 The severity of anxiety 
symptoms correlated with the intensity of pain.
Endometriosis places a considerable economic burden 
on families and on society. Delays in diagnosis, high rates 
of hospital admission, surgical procedures, and incidences 
of comorbid conditions contribute to make endometriosis a 
more costly public health problem than other chronic condi-
tions such as migraine and Crohn’s disease.9,17–21
Diagnosis and treatment  
of endometriosis
Diagnosis
Due to the variable presentation of endometriosis, there is 
typically a delay between the first appearance of symptoms 
and an accurate diagnosis. An international survey reported 
that this delay is, on average, seven years.15 Early diagnosis 
is an important objective, as endometriosis typically   follows 
a progressive course characterized by a worsening of symp-
toms in the absence of effective treatment. Errors in diag-
nosis, with the potential for inappropriate therapy, are also 
common, creating anxiety and frustration, and contributing 
further to the burden of endometriosis.
A definitive diagnosis of endometriosis requires lap-
aroscopy, ideally combined with confirmatory histology, to 
characterize endometriotic lesions.4,22 In practice, however, 
this invasive approach is considered unnecessary or inap-
propriate for many patients, and a presumptive diagnosis of 
endometriosis can be made from the symptoms alone.4
Treatment
There is no permanent cure for endometriosis. As stated 
by the American Society for Reproductive Medicine, 
“  Endometriosis should be viewed as a chronic disease that 
requires a life-long management plan with the goal of maxi-
mizing the use of medical treatment and avoiding repeated 
surgical procedures.”23 Women with endometriosis require 
ongoing, collaborative, supportive management of their con-
dition, as well as an understanding of the significant impact 
that the condition can have on their quality of life.
The main aims of treatment are to alleviate pain and other 
symptoms, reduce endometriotic lesions, and improve the 
quality of life of affected individuals. A number of medical 
and surgical therapies are available to treat endometriosis, 
which may, on occasion, be used in combination. No single 
treatment is ideal for all patients and the management 
approach chosen should be directed to the individual needs 
of each patient. As endometriosis is a chronic disease, con-
sideration should be given not only to the efficacy but also to 
the long-term safety and tolerability of the treatment options 
that are available.
Surgery
Surgical intervention includes ablation of endometriotic 
lesions, removal of endometriotic cysts, and division of 
adhesions. Surgery can provide pain relief and enhance 
fertility, but this approach should be delayed for as long as 
possible due to the high risk of recurrence, which attains a 
rate of 40%–50% at five years.24 Medications administered 
postoperatively may reduce the risk of recurrence.
Medical therapy
Nonsteroidal anti-inflammatory drugs are frequently used by 
women with endometriosis in an attempt to achieve analgesia, 
although clinical trial evidence to support the efficacy of these 
agents in endometriosis is lacking.25 A major limitation to the 
long-term use of nonsteroidal anti-inflammatory drugs is their 
significant side effects, including the risk of gastric ulceration 
and an antiovulatory effect when taken at mid-cycle.4,25
Specific medical therapies that are approved for the 
treatment of endometriosis include gonadotropin-releasing 
hormone (GnRH) agonists, danazol, and certain progestins. 
These agents and the combined oral contraceptives 
(COCs) share a common hormonal mechanism of action in 
endometriosis.
COCs are widely used to treat the symptoms of endo-
metriosis, although they are not approved for this indica-
tion in the majority of countries because of the absence of 
supportive trial evidence.26 For the same reason, practice 
guidelines can offer limited guidance on the optimal COC 
regimens in endometriosis.27 A recently published review 
notes that the putative biological effects for COCs include 
both inhibition of endometrial cell implantation but also 
a protective effect against endometrial lesion necrosis.28 
Clinical experience indicates that COCs may be used 
with safety in many women for the long-term treatment of 
  endometriosis. However, a common problem with long-term 
continuous COC regimens is breakthrough bleeding. This is 
often treated by discontinuing the COC for a few days and 
then restarting therapy.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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GnRH agonists are an established therapy for   endometriosis 
that can be administered via either intramuscular,   subcutaneous, 
or intranasal routes.29 Depot formulations are available. 
Although GnRH agonists provide effective pain relief and 
reduce the progression of endometriotic implants,29 the hypo-
estrogenic state that they induce is associated with effects 
such as accelerated bone mineral density loss, hot flushes, and 
vaginal dryness.30 In consequence, the use of GnRH agonists 
is limited to six months in the absence of “add-back” therapy 
with steroids. The optimal regimens for add-back therapy are 
not yet established.18,31 For younger women who have not yet 
reached maximum bone density, guidelines recommend a 
careful consideration of the use of GnRH agonists due to their 
bone demineralizing effects.4
Danazol is an androgenic steroid that is effective in treat-
ing the signs and symptoms of endometriosis, but its use is 
limited by adverse effects on lipid metabolism and by weight 
gain, edema, acne, vaginal dryness, hot flushes, oily skin, 
hirsutism, liver toxicity, and breast atrophy.18,32 Because of 
these effects, danazol has today been superseded in many 
countries by alternative agents.
Oral, parenteral, intrauterine, or implantable progestins 
have been used for decades in the treatment of endometriosis, 
although for many of these agents there is a lack of support-
ive evidence from controlled clinical trials. Dose-finding 
data are lacking for most progestins, and there are few 
comparative data to indicate the benefits of one progestin 
over another.
The progestins that are approved for use in endometriosis 
vary between countries. A notable example is medroxypro-
gesterone acetate injectable suspension (Depo-subQ Provera 
104™, Pfizer, New York, NY), which was approved recently 
by the US Food and Drug Administration for the treatment 
of endometriosis based on active comparator-controlled trial 
data. This medication carries a black box warning concerning 
possible bone mineral loss. The preparation is not available 
in Europe.
When administered continuously, progestins are effective in 
many women for the management of pain and other symptoms 
of endometriosis, with beneficial effects also relating to amenor-
rhea and anovulation. However, certain progestins are effective 
in endometriosis only at high doses when compared with use 
in other indications,33,34 which may increase the likelihood of 
adverse effects, such as weight gain and androgenic effects, and 
elevate the risk of cardiovascular adverse events.
Dienogest in endometriosis
Dienogest is an oral progestin that has been investigated sys-
tematically for the treatment of endometriosis in   dose-ranging, 
placebo-controlled, active   comparator-controlled, and 
  long-term trials performed in Europe and Japan (Figure 1). 
Based on this trial evidence, dienogest has received approval 
as a monotherapy for the treatment of endometriosis in 
Europe, Japan, Australia, and Singapore.
Preclinical studies
Dienogest demonstrates a number of characteristics in pre-
clinical studies that are relevant to its use in endometriosis. 
Pharmacologically, dienogest combines the advantages of the 
19-norprogestin and the progesterone derivative classes.35,36 
Dienogest binds to the progesterone receptor with high 
specificity, and produces a potent progestogenic effect related 
to the high circulating levels of the unbound molecule.37 
Binding affinities of dienogest for estrogen, glucocorticoid, 
and mineralocorticoid receptors are negligible. Unlike other 
agents in the 19-norprogestin class, dienogest lacks andro-
genic effects; rather, dienogest has beneficial antiandrogenic 
properties typical of the progesterone derivatives, which are 
associated with minimal changes in lipid and carbohydrate 
levels.38,39
Dienogest is almost completely absorbed, and has a high 
bioavailability after oral administration, similar to other 
19-norprogestins. Its relatively short half-life of 10 hours 
means there is no risk of accumulation after repeated dosing. 
OH
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Figure 1 Structural formula of the progestin, dienogest, compared with naturally occurring progesterone.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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The majority of orally administered dienogest is excreted 
within 24 hours, mainly in urine.
Dienogest reduces endometriotic lesions through a num-
ber of biological mechanisms. Dienogest is associated with 
relatively moderate inhibition of gonadotropin secretion, 
leading to a modest reduction in the endogenous production 
of estradiol.40 When given continuously, dienogest induces 
a hypoestrogenic, hypergestagenic local endocrine envi-
ronment, causing a decidualization of endometrial tissue 
followed by atrophy of the endometriotic lesions. Animal 
studies indicate that dienogest may also reduce plasma estra-
diol levels directly, through inducing apoptosis of granulosa 
cells in the ovary.41
A recent pharmacokinetic study confirmed the moderate 
suppression of estradiol levels, remaining within the lower 
end of the normal physiological range, in women volunteers 
administered dienogest at doses of 0.5–3 mg daily.42 In this 
study, ovarian activity was effectively suppressed by the 
2 mg and 3 mg doses, with a rapid return to ovulation after 
cessation of dienogest administration.
In exploratory models of endometriosis, dienogest also 
demonstrates antiproliferative, anti-inflammatory, and 
antiangiogenic effects.36,43–45 In vitro and animal studies 
show that dienogest has a direct inhibitory effect on the 
proliferation of endometrial-like tissue that is independent 
of actions via the progesterone receptor.46–49 Indirect anti-
inflammatory activity through modification of proinflamma-
tory markers has been demonstrated for dienogest in in vitro 
and in vivo experiments.50 A further potential mechanism 
of action for dienogest is inhibition of angiogenesis, which 
represents an essential stage in the development of endo-
metriotic lesions. Oral administration of dienogest signifi-
cantly suppressed angiogenesis in a mouse model.45 The 
molecular mechanisms underlying these effects continue 
to be explored.48–51
Clinical studies
Clinical studies of dienogest with durations between 12 and 
24 weeks have provided information on optimal dosing and 
on efficacy and safety characteristics that are relevant to the 
long-term management of endometriosis.
The optimal daily dose of dienogest for treating endo-
metriosis was investigated in an open-label, randomized, 
multicenter, 24-week, dose-ranging study in Europe.39 
  Sixty-eight women with endometriosis stage I–III at 
laparoscopy (ie, with minimal to moderate disease) were 
randomly assigned to treatment with dienogest 1, 2, or 4 mg 
once daily. Randomization to the 1 mg group was halted 
prematurely because of unsatisfactory bleeding patterns. 
Laparoscopy showed that dienogest at 2 mg and 4 mg daily 
significantly reduced endometriotic lesions. In addition, 
dienogest at both these doses improved patient-reported 
symptoms, including the intensity of dyspareunia, dysmenor-
rhea, and diffuse pelvic pain. The 2 mg and 4 mg dienogest 
doses were generally well tolerated and rates of discontinua-
tions due to adverse events were low. Irregular uterine bleed-
ing was experienced by 55.2% in the 2 mg group and 68.6% 
in the 4 mg group, with a trend to decreased intensity over 
time in both groups. Based on these outcomes, dienogest at 
2 mg once daily was recommended as the optimal dose in 
the treatment of endometriosis.
In support of these findings, a Japanese study investi-
gated dienogest at daily doses of 1 mg, 2 mg, and 4 mg for 
24 weeks in 183 women with endometriosis.52 The 2 mg and 
4 mg daily doses were equivalent in efficacy, measured as a 
global improvement in subjective symptoms. While safety 
assessments indicated no dose-related differences, reductions 
in estradiol levels associated with the 4 mg dose indicated 
that 2 mg daily may offer least potential for adverse effects 
on bone mineral density. Mean serum estradiol concentra-
tions at between eight weeks and the end of treatment in this 
study were 84.5, 37.4, and 26.2 pg/mL for dienogest doses of 
1, 2, and 4 mg/day, respectively. A serum estradiol concen-
tration in the range of 30–50 pg/mL is considered to fulfill 
the requirements of the estrogen threshold hypothesis,53 by 
which estrogen levels are suppressed sufficiently to inhibit 
endometriotic lesion growth, but are adequate to prevent 
hypoestrogenic side effects such as bone mineral loss. Of 
relevance to long-term compliance, 77% of the patients com-
mented that they “wanted” or “definitely wanted” to use the 
dienogest 2 mg daily dose again.
The effectiveness of dienogest at the 2 mg daily dose was 
compared against placebo in a 12-week, randomized trial 
using a range of tools for measuring changes in symptoms 
and quality of life. The study enrolled 198 women with 
stage I–IV (ie, minimal to severe) endometriosis and an 
endometriosis-associated pelvic pain score of at least 30 mm 
on a visual analog scale (measured on a scale of 0–100 mm), 
which represents a well validated tool for the measurement 
of pain.54,55 Dienogest produced a statistically significant 
decrease in the mean visual analog score compared with 
placebo, with a between-group difference of 12.3 mm in favor 
of dienogest (P , 0.0001). Biberoglu and Behrman scale 
scores supported the visual analog scores by demonstrating 
greater reductions in the intensity of symptoms and signs in 
the dienogest group compared with placebo. The Clinical International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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Global Impression scale, a measure of overall improvement, 
showed that 52.9% of the patients treated with dienogest were 
assessed by physicians to be “very much improved/much 
improved” at week 12, compared with 22.9% in the placebo 
group. Quality of life analyses based on the Short Form 36 
Health Survey questionnaire, a non-disease-specific tool used 
widely in clinical trials, showed that dienogest was associated 
with significantly greater improvement in “bodily pain” than 
placebo treatment. Dienogest was generally well tolerated in 
this trial, with no serious or unexpected adverse events, and 
few events related to therapy. Estradiol levels were modestly 
suppressed, and profiles of uterine bleeding in the dienogest 
group were comparable with the placebo group.
Three studies of 16–24 weeks’ duration have directly 
compared dienogest against GnRH agonists, a standard 
therapy in endometriosis.56–58 In a 24-week, randomized study 
of 252 women with endometriosis in Europe, dienogest 2 mg 
once daily and leuprolide acetate at standard dose (3.75 mg, 
depot intramuscular injection every four weeks) provided 
comparable, continuous reductions in pelvic pain measured 
by visual analog score. By week 24, reductions in mean visual 
analog score were 47.5 mm for dienogest and 46.0 mm for 
leuprolide acetate. Consistent with the visual analog score 
changes, dienogest and leuprolide acetate induced similar 
decreases in the intensity of symptoms and physical findings 
assessed by Biberoglu and Behrman scores. Short Form 36 
Health Survey scores showed a trend to greater improvement 
in both physical and mental health in the dienogest than the 
leuprolide acetate group. Effects of estrogen deprivation 
were substantially more common in the leuprolide acetate 
group than dienogest group, including numbers of days with 
hot flushes/week (mean 4.7 versus 0.82, respectively), while 
bleeding episodes were suppressed less with dienogest than 
leuprolide acetate. The leuprolide acetate group showed a 
reduction in mean lumbar bone mineral density, while, in 
the dienogest group, lumbar bone mineral density showed a 
small increase (P = 0.0003 versus leuprolide acetate).57
Dienogest 1 mg twice daily was compared with triptorelin 
3.75 mg (depot intramuscular injection every four weeks) 
as a postoperative medication in a 16-week, multicenter, 
open, randomized trial of 142 women with stage II–IV 
endometriosis.56 The two medications were equally effec-
tive in improving endometriosis symptoms and signs, and 
laparoscopy scores. Hot flushes were reported in 61.2% of 
women receiving the GnRH agonist compared with 9.6% of 
women treated with dienogest. Irregular bleeding was the 
most common complication in the dienogest group (61.6% 
versus 25.4% with GnRH agonist).
The third comparative trial including a GnRH agonist 
was a 24-week, randomized, double-blind, multicenter 
study   comparing dienogest 2 mg once daily against 
  intranasal   buserelin acetate 300 µg three times daily, which 
was performed in Japan in 271 women with confirmed 
  endometriosis.58 Dienogest was as effective as buserelin 
acetate in reducing endometriosis symptoms and lesion size 
at laparoscopy. Greatest changes in quality of life (assessed 
by Short Form 36 Health Survey score) in both groups 
were improvements in bodily pain, with a trend to greater 
improvement in the dienogest group. Mean lumbar bone 
mineral density decreased in both groups in this population, 
with a significantly greater reduction in the buserelin acetate 
group (P = 0030). Consistent with the other comparative tri-
als, dienogest was associated more frequently with irregular 
bleeding but less frequently with hot flushes than the GnRH 
agonist.
Notably, each of the trials that investigated dienogest 
2 mg daily described adverse effects of generally mild to 
moderate intensity which were associated with low rates 
of treatment discontinuation (eg, 5.0%57 and 4.4%58 over 
24-week treatment durations). Bleeding episodes decreased 
in number and intensity over time, and were associated with 
no discontinuations in these trials.57,58
An open-label pilot study of dienogest at the higher 
dose of 10 mg twice daily for 24 weeks provides additional 
information on the safety of this medication.59,60 Dienogest 
at 20 mg daily had no clinically relevant effect on thyroid or 
adrenal function, electrolyte balance, or hematopoiesis in the 
21 women with stage I–IV endometriosis who participated. In 
addition, dienogest at this high dose had no adverse effects on 
lipid metabolism, liver enzymes, fasting insulin, or glucose. 
No menopausal symptoms and no adverse androgen-related 
effects were reported. These observations, demonstrating 
that dienogest has a favorable safety and tolerability profile 
even at 20 mg daily (ie, 10 times the recommended dose), 
support the conclusion that the recommended dose of 2 mg 
once daily will have a similar beneficial profile.
Dienogest and fertility 
considerations
The majority of women suffering from endometriosis are of 
reproductive age and so may require contraception. Based 
on the available data, dienogest provides complete ovulation 
inhibition at a daily dose of 2 mg.37,42,61 However, dienogest 
monotherapy was not developed as a contraceptive, and 
women taking dienogest as a treatment for endometriosis are 
advised to use nonhormonal methods of contraception.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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Women with endometriosis may desire pregnancy once 
sufficient pain relief is achieved. Recent pharmacodynamic 
data in volunteers indicate that ovarian activity resumes 
  rapidly (range 1–43 days) after cessation of dienogest.42 
These observations support studies that describe a prompt 
return to fertility (eg, mean about 30 days) and include 
cases of successful pregnancy in women with endometriosis 
  following the cessation of dienogest treatment 2 mg daily for 
durations up to one year.52,62,63
As with other progestins, there are limited data on the use 
of dienogest in pregnant women. The available data do not 
indicate harmful effects for dienogest with respect to repro-
ductive toxicity and reveal no special risks on pregnancy. 
However, dienogest should not be administered to pregnant 
women because there is no need to treat endometriosis dur-
ing pregnancy.64
Dienogest for the long-term 
treatment of endometriosis
Effective management of endometriosis over the longer term 
is an important objective. The painful symptoms and impair-
ment in quality of life associated with endometriosis may 
persist or deteriorate in the absence of effective treatment. 
Recurrence is frequent even after successful surgery, while 
there are only limited trial data to confirm the efficacy and 
safety of long-term treatment for many medications used in 
endometriosis.
Dienogest has been investigated as a long-term treatment 
of endometriosis in two large trials performed in Europe and 
Japan, which included assessments of efficacy, change in 
quality of life, safety, and tolerability.
Women who completed the 12-week placebo-controlled 
study in Europe54 were offered the opportunity to enter 
an open-label extension study of dienogest for up to 53 
additional weeks, providing an overall treatment period of 
up to 65 weeks.62 Notably, of the 188 women completing 
the placebo-controlled study, a large proportion (n = 168, 
89%) consented to enter the long-term extension study. The 
intensity of pain showed significant, sustained improvements 
during the long-term study, in addition to the improvements 
associated with dienogest during the placebo-controlled 
phase. Mean visual analog scores decreased from 56.9 mm 
at baseline of the placebo-controlled study to 34.1 mm at 
baseline of the long-term study, to 11.5 mm at the end of 
the 53 additional weeks of treatment (Figure 2). During a 
24-week treatment-free period following the long-term study, 
visual analog scores increased only moderately, suggesting 
that dienogest induces a beneficial effect that may persist 
after treatment cessation. Short Form 36 Health Survey 
scores during the treatment-free period indicated minimal 
changes in physical or mental indices of quality of life over 
six months after cessation of dienogest.
During the long-term study, laboratory parameters, 
vital signs, and body weight remained stable or underwent 
minimal changes. Adverse effects considered potentially 
treatment-related developed in 16.1% of women, including 
breast discomfort (4.2%), nausea (3.0%), and irritability 
(2.4%). The maximal intensity of treatment-related adverse 
events was mild or moderate in 92.5% of cases. In agreement 
with trends observed in the 12- and 24-week studies, the 
intensity and frequency of bleeding reduced progressively 
over the course of the long-term study. During post-treatment 
follow-up, bleeding returned to normal intensity and cyclic 
patterns resumed within 4–6 weeks. Treatment compliance 
during the long-term study was high (98%) and discontinua-
tion rates due to adverse events or lack of efficacy were both 
low (2.4% and 0.6%, respectively).
The results of this long-term study performed in Europe 
are supported by a 52-week, nonrandomized trial of dienogest 
2 mg daily conducted in Japan on 135 women with confirmed 
endometriosis.63 Global improvement was measured by 
change in the severity of five subjective symptoms (lower 
abdominal pain, lumbago, dyschezia, dyspareunia, and pain 
on vaginal examination) and two objective findings (indu-
ration involving pouch of Douglas and uterine mobility). 
Moderate or marked global improvement was recorded in 
72.5% of patients after 24 weeks and in 90.6% after 52 weeks 
of dienogest treatment (Figure 3). Changes in visual analog 
score for lower abdominal pain and lumbago decreased pro-
gressively, while the proportion of patients demonstrating a 
reduction in cyst size .25% was 85% at 52 weeks. Quality 
of life assessments using the Short Form 36 Health Survey 
score indicated improvements in bodily pain by 23.57 and 
27.37 points (on a 100-point scale) at 24 and 52 weeks, 
respectively, compared with baseline. Patient satisfaction 
with dienogest at the end of treatment was high, with 88.9% 
of women responding that they were “certainly willing” or 
“would prefer” to use dienogest again.
The most commonly reported treatment-related adverse 
event was metrorrhagia (71.9%), followed by headaches 
(18.5%) and constipation (10.4%). None of the treatment-
related adverse events was rated as serious. Metrorrhagia 
resolved in 96 of the 97 affected patients either during 
the study or within two months of study cessation. The 
frequency of bleeding lessened as treatment progressed, 
so that 40.5% of women were experiencing no bleeding by International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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Note: Reprinted in part from Strowitzki T et al,54 with permission from elsevier.
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49–52 weeks. Resumption of menses was confirmed in all 
women at the end of the study. The discontinuation rate due 
to   treatment-related adverse events was 5.2%. Lumbar bone 
mineral density decreased by 1.7 ± 2.2% between baseline 
and week 52, with the greatest change in the first 24 weeks. 
The authors noted that this bone mineral density change may 
be considered mild and not significantly greater than that 
observed in untreated women of similar age. No biochemical 
markers of bone metabolism indicated changes outside the 
normal reference range.
Recently, a small open-label, nonrandomized study 
performed in Japan has investigated continued dienogest 
2 mg/day for 12 months (n = 33 women) in comparison with 
sequential treatment including GnRH agonist (leuprorelin 
acetate or buserelin acetate) for 4–6 months followed by 
dienogest 1 mg/day for 12 months (n = 38).65 Continued 
dienogest significantly reduced the mean visual analog scores 
for dysmenorrhea, nonmenstrual pelvic pain, and dyspare-
unia at six and 12 months, equivalent to the score reductions 
achieved with GnRH agonist followed by dienogest. For 
approximately 40% of women in the sequential treatment 
group, the dienogest dose was increased from 1 mg to 
1.5–2 mg/day to optimize bleeding control. Consistent with 
other studies, uterine bleeding was significantly reduced in International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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the second compared with the first six months of dienogest 
treatment. The divergence in dienogest dose hinders the inter-
pretation of bleeding rates across the treatment groups. The 
authors concluded that dienogest represents a practical and 
efficient long-term therapy in patients who respond to GnRH 
agonist therapy. The data may be interpreted also to indicate 
that continued long-term dienogest is as effective for pain 
relief as a GnRH agonist followed by dienogest therapy.
Discussion
Effective long-term management of endometriosis is a sig-
nificant clinical objective in view of the debilitating nature 
of this often chronic condition. Among current management 
approaches, recurrence is common after surgery, while evi-
dence to support the efficacy and safety of many medications 
is lacking. GnRH agonists, a standard medication in endo-
metriosis, may not be administered continuously for more 
than six months in the absence of add-back therapy because 
of the deleterious hypoestrogenic effects.
Dienogest is a progestin investigated for the treatment of 
endometriosis. Dienogest at a dose of 2 mg daily has been 
studied extensively in clinical trial programs performed in 
Europe and Japan, including two studies with treatment 
durations of up to 65 weeks. These studies demonstrated that 
dienogest has an efficacy, safety, and tolerability profile that is 
favorable for long-term use. The intensity of pain associated 
with endometriosis decreased progressively, adverse events 
(mostly mild or moderate in intensity) were predictable and 
associated with low discontinuation rates, and bleeding 
irregularities reduced in intensity and frequency over time. 
Following cessation of dienogest treatment, menses returned 
to normal.
The impact of endometriosis on a woman’s quality of life 
is substantial and wide ranging. Quality of life assessments 
in the dienogest studies indicated that improvements in both 
physical and mental indices were attained within 12-week 
and 24-week treatment durations, and that these benefits were 
sustained in studies of up to one year.
Also of major significance to clinical practice, compli-
ance with dienogest treatment was high and rates of discon-
tinuation due to adverse events were low in these studies. 
Contributors to this favorable compliance may include the 
efficacy of dienogest for symptom control and the predict-
ability of adverse effects, which can be communicated to 
patients before treatment initiation. Large proportions of 
the women who were questioned expressed a willingness to 
continue dienogest treatment.
Together, the dienogest study programs performed 
in Europe and Japan indicate that dienogest represents a 
promising new medication for the long-term management 
of endometriosis.
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